

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

<b>1. Name and Address of Reporting Person*</b> <u>Or Yat Sun</u>  (Last) (First) (Middle) <u>C/O ENANTA PHARMACEUTICALS,</u> <u>INC.</u> <u>500 ARSENAL STREET</u>  (Street) <u>WATERTOWN MA</u> <u>02472</u>  (City) (State) (Zip)	<b>2. Date of Event Requiring Statement (Month/Day/Year)</b> <u>03/20/2013</u>	<b>3. Issuer Name and Ticker or Trading Symbol</b> <u>ENANTA PHARMACEUTICALS INC [ ENTA ]</u>  <b>4. Relationship of Reporting Person(s) to Issuer (Check all applicable)</b> Director    10% Owner <input checked="" type="checkbox"/> Officer (give title below)                      Other (specify below) <p style="text-align: center;"><u>Chief Scientific Officer</u></p>	<b>5. If Amendment, Date of Original Filed (Month/Day/Year)</b>  <b>6. Individual or Joint/Group Filing (Check Applicable Line)</b> <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
---	---	--	---

### Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>79,991</u>	<u>D</u>	

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Stock Option (right to buy)</u>	<u>(1)</u>	<u>07/01/2014</u>	<u>Common Stock</u>	<u>121,837</u>	<u>0.73</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(1)</u>	<u>12/23/2014</u>	<u>Common Stock</u>	<u>7,250</u>	<u>0.73</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(1)</u>	<u>06/23/2016</u>	<u>Common Stock</u>	<u>11,149</u>	<u>1.29</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(1)</u>	<u>07/12/2017</u>	<u>Common Stock</u>	<u>50,723</u>	<u>2.97</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(1)</u>	<u>07/11/2018</u>	<u>Common Stock</u>	<u>13,921</u>	<u>1.98</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(1)</u>	<u>03/05/2019</u>	<u>Common Stock</u>	<u>13,921</u>	<u>1.51</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(1)</u>	<u>05/25/2020</u>	<u>Common Stock</u>	<u>6,960</u>	<u>1.21</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(2)</u>	<u>06/18/2020</u>	<u>Common Stock</u>	<u>51,044</u>	<u>1.21</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(1)</u>	<u>04/15/2021</u>	<u>Common Stock</u>	<u>13,921</u>	<u>2.54</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(3)</u>	<u>06/17/2021</u>	<u>Common Stock</u>	<u>5,800</u>	<u>2.54</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(4)</u>	<u>09/23/2021</u>	<u>Common Stock</u>	<u>23,201</u>	<u>2.54</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(1)</u>	<u>06/20/2022</u>	<u>Common Stock</u>	<u>13,921</u>	<u>11.77</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(5)</u>	<u>06/20/2022</u>	<u>Common Stock</u>	<u>4,872</u>	<u>11.77</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>(6)</u>	<u>12/26/2022</u>	<u>Common Stock</u>	<u>13,921</u>	<u>14.18</u>	<u>D</u>	

**Explanation of Responses:**

1. 100% of the shares subject to the option are fully vested and exercisable.
2. 50% of the shares subject to the option became fully vested and exercisable as of June 18, 2010 (the "Grant Date"), and the remaining shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Grant Date.
3. 50% of the shares subject to the option became fully vested and exercisable as of June 17, 2011 (the "Grant Date"), and the remaining shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Grant Date.
4. 50% of the shares subject to the option became fully vested and exercisable as of September 23, 2011 (the "Grant Date"), and the remaining shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Grant Date.
5. 50% of the shares subject to the option became fully vested and exercisable as of June 20, 2012 (the "Grant Date"), and the remaining shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Grant Date.
6. The shares subject to the option will become fully exercisable on December 31, 2013.

**Remarks:**
/s/ Yat Sun Or
03/20/2013

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Jay R. Luly, Paul J. Mellett, and Nathaniel S. Gardiner, or each of them acting individually, the undersigned's true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned a Form ID application to be filed with the Securities and Exchange Commission to obtain EDGAR codes for the undersigned;

(2) execute for and on behalf of the undersigned Forms 3, 4, and 5 with respect to the securities of Enanta Pharmaceuticals, Inc. (the "Company") in accordance with Section 16(a) of the Securities and Exchange Act of 1934 and the rules thereunder;

(3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID application or Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such forms with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(4) take any other action of any

type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's

responsibilities to comply with  
Section 16 of the Securities  
Exchange Act of 1934, as amended.

This Power of Attorney shall  
remain in full force and effect  
until the undersigned is no longer  
required to file Forms 3, 4, and 5  
with respect to the undersigned's  
holdings of and transactions in  
securities issued by the Company,  
unless earlier revoked by the  
undersigned in a signed writing  
delivered to the foregoing attorneys-  
in-fact.

IN WITNESS WHEREOF, the undersigned  
has caused this Power of Attorney to  
be executed this 20th day of March  
2013.

/s/ Yat Sun Or